Santen to troll for Eisai ophthalmic candidates under option deal
This article was originally published in Scrip
Executive Summary
In a sign of its tightening strategic focus on core therapeutic areas such as oncology and CNS, Eisai has given fellow Japanese firm and eye care specialist Santen option rights to its portfolio of molecules with potential ophthalmic uses.